Brain gene therapy aims to boost dopamine in young Parkinson's patients
Disease control
Not yet recruiting
This early-stage trial tests a gene therapy called AAV2-hAADC in 9 adults with young-onset Parkinson's disease. The therapy delivers a gene directly to two brain regions (putamen and caudate) to help convert levodopa into dopamine more efficiently. The main goal is to check safet…
Phase: PHASE1 • Sponsor: Krzysztof Bankiewicz • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC